Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Texas MPN Workshop 2022 | The promise of pelabresib in MF and insights into the MANIFEST-2 study

Andrew Kuykendall • 26 Aug 2022
Texas MPN Workshop 2022
Myelofibrosis Myeloproliferative Neoplasms Pelabresib Ruxolitinib
MANIFEST MANIFEST-2

In this video, Andrew Kuykendall, MD, H. Lee Moffitt Cancer Center, Tampa, FL, discusses the promising role of pelabresib in myelofibrosis (MF), and shares some insights into the excitement surrounding the ongoing Phase III MANIFEST-2 study (NCT04603495). This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

Disclosures

Research fees – Morphosys, GSK
Honoraria – Incyte

More from Andrew Kuykendall

1:44
Predicting thrombocytopenia as a result of ruxolitinib treatment in MF
Andrew Kuykendall • 27 Nov 2023
2:06
Thromboembolic event rates in patients with PV: a real-world analysis
Andrew Kuykendall • 27 Nov 2023
2:03
Preliminary results of a Phase II study of fedratinib in patients with MDS/MPN and CNL
Andrew Kuykendall • 27 Nov 2023
1:40
Challenges and options for patients with hydroxyurea-resistant PV
Andrew Kuykendall • 27 Nov 2023

Related Videos

1:35
Addressing the increased risk of cardiovascular disease in patients with MPNs
Arjun Ghosh • 25 Apr 2024
2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals